2012 Fiscal Year Final Research Report
Screening for therapies of diabetes targeting novel hepatokine selenoprotein P that induces insulin resistance
| Project/Area Number |
23791022
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
MISU Hirofumi 金沢大学, 医薬保健学総合研究科, 特任助教 (80447680)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Keywords | エネルギー / 糖代謝異常 / ヘパトカイン |
|---|
| Research Abstract |
Antidiabetic drug metformin was shown to reduce selenoprotein P gene expression via AMP kinase/Foxo3 pathway in the cultured hepatocytes. Membrane protein X was identified as a strong candidate of the receptor of selenoprotein P in C2C12 myocytes. It is expected that AMPK/Foxo3 pathway in the liver and seenoprotein P/membrane protein 1 pathway in the muscle are novel therapeutic targets for type 2 diabetes.
|
